Transgene Secures a €20 Million Revolving Credit Facility with Natixis

STRASBOURG, France–(BUSINESS WIRE)–

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that
designs and develops virus-based immunotherapies against cancers and
infectious diseases, announces that it has secured a €20 million
revolving credit facility with Natixis, the French Corporate and
Investment bank.

The credit facility will have a 30-month term and Transgene will be able
to draw on and repay the facility at its discretion.

Transgene has used its shares in the Chinese biotech company Tasly
Biopharmaceuticals as collateral for this loan. As a reminder, Transgene
became a Tasly Biopharmaceuticals shareholder in July 2018 and holds
2.5% of its capital as the result of a series of agreements under which
Transgene transferred to Tasly Biopharmaceuticals its Chinese rights to
T601 and T101, two immunotherapies discovered by Transgene and which are
currently being developed by Tasly Biopharmaceuticals in Greater China.
Tasly Biopharmaceutials has announced its intention to list its shares
on the Hong Kong Stock Exchange.

Jean-Philippe Del, Vice President, Finance, said: “I am glad
that we have been able to monetize our shareholding in Tasly
Biopharmaceutical to extend our cash runway. With this new loan
facility, we now have the funds needed to support our clinical and
pre-clinical activities until mid-2020.”